- Potentially ground-breaking treatment for the world’s greatest unmet medical need
- Lucidity trial is the only late-stage clinical trial target the Tau pathology of Alzheimer’s
- Trial aims to confirm efficacy of first tau-based disease modifying treatment for Alzheimer’s
Aberdeen, Scotland and Singapore [28 January 2021] – TauRx Pharmaceuticals Ltd, the global leader in tau-based research in treatments for Alzheimer’s disease (AD), today announced it has completed patient enrolment for the forthcoming Lucidity trial (NCT03446001) ahead of schedule.
Lucidity is the only late-stage clinical trial targeting the tau pathology of Alzheimer’s disease (AD). With more than 500 patients, the trial aims to confirm the efficacy of hydromethylthionine (known as LMTM) and support regulatory approval of the drug as the first tau-based disease modifying treatment for Mild Cognitive Impairment and Mild-Moderate AD.
Tau aggregation is now generally understood to be more correlated with clinical decline and reduction in brain metabolism than deposition of amyloid – the main target in clinical trials for the last 20 years.
At the recent J.P. Morgan 39th Annual Healthcare Conference and Biotech Showcase, TauRx data analyses compared cognitive and functional decline in patients receiving LMTM as their sole treatment, with the decline expected on the basis of other reported trial placebo and public data available for comparison. Whereas patients with low blood levels of the drug declined as expected those with levels in the therapeutic range had significantly less decline over 12 months on measures of cognition and general daily function – a reduction of 74% - 100% depending on disease severity. Read more here.
Aberdeen, Scotland and Singapore [28 January 2021] – TauRx Pharmaceuticals Ltd, the global leader in tau-based research in treatments for Alzheimer’s disease (AD)
